Supplementary MaterialsAppendix EMMM-12-e11656-s001. optimize funding and research support. Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic syndrome caused by mutations in the gene (Gutmann protein product, neurofibromin, negatively regulates Ras signal\transduction pathways. Several preclinical studies validated mitogen\activated protein kinase (MEK), a component of the Ras\Raf\MEK\ERK signaling cascade, as a potential therapeutic target for NF1 tumors and other manifestations. At least four MEK inhibitors, mirdametinib (PD0325901), trametinib (GSK1120212, Mekinist), binimetinib (ARRY\438162, MEK162), and selumetinib (AZD6244), have progressed to clinical trials in NF1 patients and, at the time of writing, ClinicalTrials.gov lists 23 trials to evaluate these MEK inhibitors for Urocanic acid various manifestations of NF1 (Table?1). Selumetinib was granted Orphan Urocanic acid Drug Designation and Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency Urocanic acid (EMA) based on encouraging results in pediatric NF1 patients with inoperable pNFs (Dombi em et?al /em , 2016). If approved, selumetinib will be the first drug to treat NF1\associated tumors. Table 1 Ongoing MEK inhibitor scientific trials for circumstances including NF1a thead valign=”best” th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ ClinicalTrials.gov identifier /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Involvement Urocanic acid /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Research name /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Stage /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Recruitment position /th /thead “type”:”clinical-trial”,”attrs”:”text message”:”NCT02096471″,”term_identification”:”NCT02096471″NCT02096471PD\0325901MEK Inhibitor PD\0325901 Trial in Children and Adults With NF1 (MEK Inhibitor)Stage 2Completed”type”:”clinical-trial”,”attrs”:”text message”:”NCT03962543″,”term_identification”:”NCT03962543″NCT03962543Mirdametinib (PD\0325901)MEK Inhibitor Mirdametinib (PD\0325901) in Sufferers With Neurofibromatosis Type 1\Associated Plexiform NeurofibromasPhase 2Not Yet Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT02124772″,”term_identification”:”NCT02124772″NCT02124772Trametinib, DabrafenibStudy to research Protection, Pharmacokinetic Urocanic acid (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Topics With Tumor or Plexiform Neurofibromas and Trametinib in conjunction with Dabrafenib in Topics With Malignancies Harboring V600 MutationsPhase 1/2aRecruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT03363217″,”term_identification”:”NCT03363217″NCT03363217TrametinibTrametinib for Pediatric Neuro\oncology Sufferers With Refractory Tumor and Activation from the MAPK/ERK PathwayPhase 1/2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT03190915″,”term_identification”:”NCT03190915″NCT03190915TrametinibTrametinib in Treating Sufferers With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaPhase 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT03232892″,”term_identification”:”NCT03232892″NCT03232892TrametinibTrametinib in Sufferers With Advanced Neurofibromatosis Type 1 (NF1)\Mutant Non\Little\Cell Lung CancerPhase 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT02465060″,”term_identification”:”NCT02465060″NCT02465060TrametinibTargeted Therapy Directed by Genetic Tests in Treating Sufferers With Advanced Refractory Good Tumors, Lymphomas, or Rabbit Polyclonal to MAST1 Multiple Myeloma (The MATCH Verification Trial)Stage 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT03741101″,”term_identification”:”NCT03741101″NCT03741101TrametinibTreatment of NF1\related Plexiform Neurofibroma With TrametinibPhase 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT01885195″,”term_identification”:”NCT01885195″NCT01885195BinimetinibMEK162 for Sufferers With RAS/RAF/MEK\Activated Tumors (Personal)Stage 2Completed”type”:”clinical-trial”,”attrs”:”text message”:”NCT03231306″,”term_identification”:”NCT03231306″NCT03231306BinimetinibPhase II Research of Binimetinib in Kids and Adults With NF1 Plexiform Neurofibromas (NF108\BINI)Stage 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT02285439″,”term_identification”:”NCT02285439″NCT02285439BinimetinibPhase We/II Research of MEK162 for Kids With Ras/Raf Pathway\Activated TumorsPhase 1/2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT01089101″,”term_identification”:”NCT01089101″NCT01089101SelumetinibSelumetinib in Treating Little Sufferers With Recurrent or Refractory Low\Quality GliomaPhase 1/2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT01362803″,”term_identification”:”NCT01362803″NCT01362803SelumetinibAZD6244 Hydrogen Sulfate (Selumetinib) for Kids With Nervous Program TumorsPhase 2Active, not recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT02407405″,”term_identification”:”NCT02407405″NCT02407405SelumetinibSelumetinib in Treating Sufferers With Neurofibromatosis Type 1 and Plexiform Neurofibromas That CAN’T BE Removed by SurgeryPhase 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT02839720″,”term_identification”:”NCT02839720″NCT02839720SelumetinibSelumetinib in Treating Sufferers With Neurofibromatosis Type 1 and Cutaneous NeurofibromaPhase 2Recruiting”type”:”clinical-trial”,”attrs”:”text message”:”NCT03109301″,”term_identification”:”NCT03109301″NCT03109301SelumetinibMitogen\Activated Proteins Kinase Kinase (MEEK/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in PEOPLE WHO HAVE Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)Stage 2Withdrawn”type”:”clinical-trial”,”attrs”:”text”:”NCT03213691″,”term_id”:”NCT03213691″NCT03213691SelumetinibSelumetinib in Treating Patients With Relapsed or Refractory Advanced Sound Tumors, Non\Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Phase 2Recruiting”type”:”clinical-trial”,”attrs”:”text”:”NCT03259633″,”term_id”:”NCT03259633″NCT03259633SelumetinibAn Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1Expanded accessAvailable”type”:”clinical-trial”,”attrs”:”text”:”NCT03326388″,”term_id”:”NCT03326388″NCT03326388SelumetinibIntermittent Dosing Of Selumetinib In Childhood NF1\Associated Tumors (INSPECT)Phase 1/2Not yet recruiting”type”:”clinical-trial”,”attrs”:”text”:”NCT03649165″,”term_id”:”NCT03649165″NCT03649165SelumetinibA Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male ParticipantsPhase 1Completed”type”:”clinical-trial”,”attrs”:”text”:”NCT03433183″,”term_id”:”NCT03433183″NCT03433183SelumetinibSARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsPhase 2Recruiting”type”:”clinical-trial”,”attrs”:”text”:”NCT03871257″,”term_id”:”NCT03871257″NCT03871257Selumetinib, Carboplatin/VincristineA Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low\Grade GliomaPhase 3Not yet recruiting”type”:”clinical-trial”,”attrs”:”text”:”NCT03975829″,”term_id”:”NCT03975829″NCT03975829Trametinib DabrafenibPediatric Long\Term Follow\up and Rollover StudyPhase 4Not yet recruiting Open in a separate window aSearch done on clinicaltrial.gov on August 26, 2019. Funding landscape in NF The funding landscape of NF1\MEK research, and of NF1 research as a whole, continues to be shaped with the initiatives of multiple philanthropic and federal government agencies world-wide. As well as the National Institutes of Health (NIH, intramural and extramural), the study and organizations programs which have played an essential role in advancing.